Ascelia Pharma: Easing financial pressure - Redeye

A SEK 20m to SEK 35m financing based with the financial partner Formue Nord Fokus A/S eases the financial pressure ahead of the SPARKLE results and the following year. We expect at least a 10% positive share price reaction due to the easing pressure. Ahead of Ascelia’s Q4 on Friday, our existing base case valuation is SEK 8, Bull Case of SEK 26, and Bear Case of SEK 2.

Länk till analysen i sin helhet: https://www.redeye.se/research/974598/ascelia-pharma-easing-financial-pressure?utm_source=finwire&utm_medium=RSS